NorthWest Biotherapeutics Inc (NWBO)

[OncoJock]

You make some very good points, Gary. Thank you. NWBO would indeed need new information that has never been presented anywhere else to gain approval from the ASCO peer reviewers to present an abstract at the 2023 main annual meeting. A re-hash of the phase 3 trial results, published in JAMA Oncology in November, would not be sufficient.

You also raise a terrific point about the importance of the combination trials currently underway at UCLA, namely, adjuvant ATL-DC + PD-1 mAb. The slide showing interim survival analysis among patients with recurrent GBM (>50% at 2 years), shared by Dr. Liau late last year, is really intriguing even though the number of patients is small. Perhaps Dr. Prins or Cloughesy will submit an abstract, if Dr. Liau is too busy with teaching/administrative duties as department chair.

Best wishes,

-- OJ